Karma Biotechnologies
ClosedLos Angeles · Founded 2017
- Headquarters
- Los Angeles
- Founded
- 2017
- Website
- karmabiotech.com
- Last Round
- SeedOct 2023
- Rounds
- 1
About
Karma Biotechnologies is an oncology startup developing lipid nanoparticle (LNP) systems for localized delivery of DNA and RNA payloads to solid tumors, initially targeting colorectal cancer and other hard-to-penetrate tumors. The company's proprietary LNPs deliver DNA and RNA payloads without electroporation and can transfect macrophages that home to tumor sites, localizing biologics such as IL-15 to convert cold tumors into more immunologically active ones. Karma was an SOSV/IndieBio portfolio company.
Summary
Karma Biotechnologies is a Biotech company based in Los Angeles, founded in 2017. Its most recent funding was a Seed round in Oct 2023. Investors include SOSV, IndieBio and Tuesday Capital.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2023
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.